|
Other - Net, Expense (Income) (Details) (USD $)
In Millions, unless otherwise specified |
3 Months Ended | 12 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 31, 2014
|
Sep. 30, 2014
|
Jun. 30, 2014
|
Mar. 31, 2014
|
Dec. 31, 2013
|
Sep. 30, 2013
|
Jun. 30, 2013
|
Mar. 31, 2013
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2012
|
|
| Other Revenue, Net | $ 788.4 | $ 707.5 | $ 633.0 | ||||||||
| Income related to termination of the exenatide collaboration with Amylin | 0 | (495.4) | (787.8) | ||||||||
| Interest Expense | 148.8 | 160.1 | 177.8 | ||||||||
| Investment Income, Interest | (121.0) | (119.7) | (105.0) | ||||||||
| Other (income)expense | (368.3) | (63.9) | 41.0 | ||||||||
| Nonoperating Income (Expense), Total | (137.2) | (93.5) | (53.8) | (56.0) | (9.1) | 31.3 | (11.9) | (529.2) | (340.5) | (518.9) | (674.0) |
| Exenatide [Member] | |||||||||||
| Other Revenue, Net | 0 | 70.1 | |||||||||
| Other (income)expense | $ (495.4) | $ (787.8) | |||||||||